Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

About Michael Silber

This author has not yet filled in any details.
So far Michael Silber has created 2781 blog entries.

Oregon

The Department of Consumer and Business Services (DCBS) Division of Financial Regulation announced the Prescription Drug Price Transparency (DPT) Program published PBM data results and analysis from its third year of collecting this data. This year, it received data for calendar year 2025. The payments PBMs received from manufacturers and reported to DPT for Oregon covered lives were more than $217 million. Most of these manufacturer payments – almost $210 million – were passed to insurers. The remainder of the payments were retained by the PBM or its affiliate ($6.4 million) or passed to enrollees ($875,000). Additionally, PBMs retained administrative fees of $25.8 million, four-fifths of the total ($20.1 million) from insurers and one-fifth ($5.7 million) from manufacturers. Refer to the published PBM data for additional details. For more information, contact the department at rx.prices@dcbs.oregon.gov.

Also in Oregon, the Board of Pharmacy adopted the following Temporary Rule and Vaccine Protocols during the September 18 special board meeting. While the Oregon Health Authority State of Oregon Statewide Standing Order is still valid, pharmacists should transition to using the Board’s Coronavirus 19 Protocol v. 09/2026 as their primary source of authority for prescribing/dispensing/administering COVID-19 vaccines.

September 22: Temporary Rule & Vaccine Protocols Noticed

Email all rulemaking related inquiries to pharmacy.rulemaking@bop.oregon.gov.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2026-10-02T15:18:29-04:00October 2, 2026|Oregon|

Texas

NACDS and the Texas Federation of Drug Stores (TFDS) are launching a series of three Advocacy Training sessions in Dallas/Fort Worth, Houston and Austin. These events are designed to empower Texas pharmacists, technicians and interns to become influential voices at the Capitol ahead of the pivotal 2027 legislative session. With both in-person and virtual participation options, attendees will gain insider knowledge and actionable strategies on the most pressing pharmacy issues—building critical advocacy skills and a powerful professional network.

Also in Texas, the Chairman of the House Committee on Public Health, Rep. Gary Van Deaver (R), who wasn’t seeking a 7th term, suddenly resigned from the Texas House of Representatives this week to take a position as the new Executive Director of the Texas Association of School Boards.

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2026-10-02T15:17:57-04:00October 2, 2026|Texas|

California

Notice is hereby given that the Board of Pharmacy (hereafter Board) has proposed modifications made to proposed regulation 16 CCR section 1707.4 related to Central Fill Pharmacies. These regulations were originally noticed on October 17, 2025, and again February 23, 2026, and approved as modified by the Board at its September 17 Board meeting.  

Materials regarding this proposal can be found online or by requesting them from the Contact Person identified below. 

Any person who wishes to comment on the proposed modifications may do so by submitting written comments between September 18 and October 2 to the
following: 

Contact Name: Debbie Damoth
Address: 2720 Gateway Oaks Drive, Suite 100 Sacramento, CA 95834 
Fax number: 916-574-8618 

Email Address: PharmacyRulemaking@dca.ca.gov    

Please note, comments should be restricted to the most recent modifications made to the proposed regulations. Added text is indicated with a bold double underline. Deleted text is indicated by bold double strikeout. The Board is not required to respond to comments on other aspects of the proposed regulations received in response to this notice. 

Any comments previously submitted remain in the rulemaking file and will be responded to by the Board's staff as part of the Final Statement of Reasons. All written comments received by October 2 that pertain to these modifications will be reviewed and responded to by the Board's staff as part of the compilation of the rulemaking file. 

Notice is hereby given that the following document is being added to the rulemaking record for proposed regulation 16 CCR section 1707.4 related to Central Fill Pharmacies:
 

  1. Assembly Bill No. 1503 (Berman, Chapter 196, Statutes of 2025)

 

The above document is now available for public inspection during regular business hours of 8:00 am to 5:00 pm, Monday through Friday, at the Board's office located at 2720
Gateway Oaks Dr., Ste. 100, Sacramento, CA 95833. 

Any person who wishes to comment on the proposed modifications may do so by submitting written comments by October 2 to the following: 

Contact Name: Debbie Damoth
Address: 2720 Gateway Oaks Drive, Suite 100
Sacramento, CA 95834
Fax number: 916-574-8618
Email Address: PharmacyRulemaking@dca.ca.gov 

Also in California, Notice is hereby given that the Board of Pharmacy (hereafter Board) has proposed modifications made to proposed regulation 16 CCR section 1749, related to Fee Schedule. These regulations were originally noticed on July 31 and approved as modified by the Board at its September 17 meeting. 

Materials regarding this proposal can be found at online or by requesting them from the Contact Person identified below. 

Any person who wishes to comment on the proposed modifications may do so by submitting written comments between September 17 and October 2 to the following: 

Contact Name: Brianna Fujimoto
Address: Board of Pharmacy
2720 Gateway Oaks Drive, Ste. 100
Sacramento, CA 95833
Fax number: 916-574-8618
Email Address: PharmacyRulemaking@dca.ca.gov 

Please note, comments should be restricted to the most recent modifications made to the proposed regulations. Added text is indicated with a double underline. Deleted text is indicated by double strikethrough. The Board is not required to respond to comments on other aspects of the proposed regulations received in response to this notice. 

Also in California, Gov. Gavin Newsom (D) Proclaimed a State of Emergency statewide due to the developing 2026-2027 El Nino event.  

Finally in California, the Department of Health Care Services (DHCS) posted the following on the Medi-Cal Rx Web Portal: Mass Adjustment for Vaccines Reimbursement for Members 19 Years of Age and Older for Impacted Claims with a Date of Service October 1, 2024, through December 31, 2024. 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

For more information, please contact NACDS’ Mike Sargent at 207-272-6435.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

For more information, contact NACDS’ Jermaine Smith at 703–837–4388.

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2026-09-25T12:58:50-04:00September 25, 2026|California|

Florida

Attorney General James Uthmeier filed a lawsuit against the three manufacturers that supply more than 90 percent of the world’s insulin, Eli Lilly, Novo Nordisk and Sanofi, the three pharmacy benefit managers that process roughly 80 percent of U.S. prescriptions, CVS Caremark, Express Scripts and OptumRx, and rebate aggregators Zinc, Ascent and Emisar.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

2026-09-25T12:57:01-04:00September 25, 2026|Florida|

Nebraska

The Department of Health and Human Services posted the draft agenda for the Medicaid Drug Utilization Review (DUR) Board's October 27 meeting.   

Also in Nebraska, the Department of Health and Human Services recently revised the fee schedule for Durable Medical Equipment, Medical Supplies, Orthotics and Prosthetics, that was effective September 14. 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2026-09-25T12:55:42-04:00September 25, 2026|Nebraska|

North Carolina

The next Board of Pharmacy election will begin on November 1 and will be for two positions: the northern district position, presently held by Keith Vance, and the western district position, presently held by Chris Sain. Dr. Vance is currently serving his second consecutive five-year term and is thus term limited. Dr. Sain is currently serving his first term and is eligible to run in this upcoming election. 
 
The northern district comprises Alamance, Caswell, Forsyth, Guilford, Orange, Person, Rockingham, Stokes, Surry and Yadkin Counties. 
 
The western district comprises Alexander, Alleghany, Ashe, Avery, Buncombe, Burke, Caldwell, Catawba, Cherokee, Clay, Cleveland, Gaston, Graham, Haywood, Henderson, Jackson, Lincoln, Macon, Madison, McDowell, Mitchell, Polk, Rutherford, Swain, Transylvania, Watauga, Wilkes and Yancey Counties. 
 
October 1 is the deadline for a candidate to submit their notice of intent to run and a supporting petition signed by at least ten (10) pharmacists who reside in that district. Contact  Kristin Moore for petition logistics or, to learn more about serving on the Board of Pharmacy, contact Executive Director, Jay Campbell.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

2026-09-25T12:55:06-04:00September 25, 2026|North Carolina|

Ohio

The Board of Pharmacy is seeking stakeholder comments on a new rule governing shared services, remote pharmacy functions and automated distributions systems. NACDS is working with members on the issue and intends to submit comments by the September 30 deadline. 

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

2026-09-25T12:54:21-04:00September 25, 2026|Ohio|

Oregon

The Board of Pharmacy posted the October 7-9 Board Meeting Agenda and meeting materials. Note the discussion of vaccine protocols on October 8 under agenda item “2. Rules Policy Discussion Items”. The Public may attend the board meeting in person or virtually during Open Session. Please see the meeting agenda for additional information. Also, additional meeting materials may be added to the agenda prior to the board meeting. Visit the board website for current meeting materials.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2026-09-25T12:53:30-04:00September 25, 2026|Oregon|
Go to Top